Compare LZB & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZB | AMLX |
|---|---|---|
| Founded | 1927 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 1994 | 2021 |
| Metric | LZB | AMLX |
|---|---|---|
| Price | $39.63 | $17.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $39.00 | $21.56 |
| AVG Volume (30 Days) | 743.9K | ★ 1.7M |
| Earning Date | 06-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | 5.11 | ★ 65.46 |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $2,349,433,000.00 | $380,786,000.00 |
| Revenue This Year | $1.89 | N/A |
| Revenue Next Year | $2.09 | N/A |
| P/E Ratio | $16.24 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $29.03 | $5.98 |
| 52 Week High | $44.90 | $19.15 |
| Indicator | LZB | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.66 | 66.78 |
| Support Level | $36.31 | $12.17 |
| Resistance Level | $39.76 | $18.61 |
| Average True Range (ATR) | 1.73 | 1.03 |
| MACD | -0.01 | 0.36 |
| Stochastic Oscillator | 46.29 | 78.03 |
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.